Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Acute Coronary Syndrome | 56 | 2021 | 2337 | 5.040 |
Why?
|
Adamantane | 23 | 2021 | 173 | 4.890 |
Why?
|
Dipeptides | 22 | 2021 | 409 | 4.450 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 20 | 2022 | 293 | 3.560 |
Why?
|
Myocardial Infarction | 85 | 2024 | 11727 | 3.310 |
Why?
|
Acetanilides | 20 | 2014 | 168 | 2.870 |
Why?
|
Diabetes Mellitus, Type 2 | 49 | 2024 | 11725 | 2.690 |
Why?
|
Platelet Aggregation Inhibitors | 36 | 2021 | 3068 | 2.640 |
Why?
|
Lactones | 21 | 2021 | 329 | 2.420 |
Why?
|
Heart Arrest | 14 | 2022 | 1470 | 2.030 |
Why?
|
Ticlopidine | 16 | 2016 | 899 | 1.840 |
Why?
|
Hypothermia, Induced | 9 | 2020 | 752 | 1.800 |
Why?
|
Natriuretic Peptide, Brain | 19 | 2024 | 1573 | 1.760 |
Why?
|
Heart Failure | 41 | 2024 | 10900 | 1.760 |
Why?
|
Angina, Unstable | 15 | 2016 | 926 | 1.680 |
Why?
|
Piperazines | 23 | 2015 | 2488 | 1.670 |
Why?
|
Electrocardiography | 38 | 2021 | 6442 | 1.650 |
Why?
|
Troponin | 8 | 2023 | 524 | 1.630 |
Why?
|
Angina Pectoris | 10 | 2015 | 977 | 1.430 |
Why?
|
Hypoglycemic Agents | 17 | 2022 | 2872 | 1.420 |
Why?
|
Chest Pain | 6 | 2023 | 1114 | 1.310 |
Why?
|
Pyridines | 22 | 2021 | 2825 | 1.280 |
Why?
|
Cardiovascular Diseases | 33 | 2024 | 15165 | 1.220 |
Why?
|
Hypertension | 10 | 2023 | 8480 | 1.200 |
Why?
|
Benzazepines | 5 | 2019 | 326 | 1.120 |
Why?
|
Double-Blind Method | 55 | 2021 | 12026 | 1.070 |
Why?
|
Death, Sudden, Cardiac | 9 | 2021 | 1541 | 1.070 |
Why?
|
Secondary Prevention | 15 | 2024 | 1530 | 1.050 |
Why?
|
Receptor, PAR-1 | 9 | 2019 | 113 | 1.040 |
Why?
|
Risk Assessment | 40 | 2023 | 23338 | 1.000 |
Why?
|
Adenosine | 7 | 2016 | 825 | 1.000 |
Why?
|
Troponin T | 9 | 2023 | 754 | 0.930 |
Why?
|
Receptors, Thrombin | 5 | 2017 | 131 | 0.880 |
Why?
|
Arrhythmias, Cardiac | 5 | 2018 | 2268 | 0.850 |
Why?
|
C-Reactive Protein | 8 | 2024 | 3778 | 0.830 |
Why?
|
Serotonin 5-HT2 Receptor Agonists | 2 | 2019 | 31 | 0.830 |
Why?
|
Pheochromocytoma | 2 | 2021 | 337 | 0.830 |
Why?
|
Thrombolytic Therapy | 16 | 2021 | 2161 | 0.810 |
Why?
|
Metanephrine | 1 | 2021 | 26 | 0.800 |
Why?
|
Appetite Depressants | 2 | 2019 | 110 | 0.800 |
Why?
|
Glomerular Filtration Rate | 9 | 2023 | 2170 | 0.790 |
Why?
|
Thrombotic Microangiopathies | 1 | 2023 | 132 | 0.790 |
Why?
|
Aerospace Medicine | 1 | 2022 | 84 | 0.780 |
Why?
|
Coronary Artery Disease | 16 | 2021 | 6487 | 0.780 |
Why?
|
Hypoxia, Brain | 2 | 2013 | 133 | 0.780 |
Why?
|
Tachycardia, Ventricular | 4 | 2016 | 1273 | 0.770 |
Why?
|
Renal Insufficiency, Chronic | 7 | 2024 | 2208 | 0.770 |
Why?
|
Glucosides | 7 | 2024 | 451 | 0.760 |
Why?
|
Aged | 142 | 2024 | 163280 | 0.750 |
Why?
|
Diabetic Cardiomyopathies | 2 | 2019 | 96 | 0.730 |
Why?
|
Potassium | 2 | 2016 | 1336 | 0.720 |
Why?
|
Humans | 244 | 2024 | 744343 | 0.720 |
Why?
|
Out-of-Hospital Cardiac Arrest | 2 | 2022 | 339 | 0.700 |
Why?
|
Hypercholesterolemia | 2 | 2023 | 1151 | 0.700 |
Why?
|
Male | 169 | 2024 | 350118 | 0.690 |
Why?
|
Middle Aged | 141 | 2023 | 213383 | 0.690 |
Why?
|
Hospitalization | 27 | 2023 | 10262 | 0.690 |
Why?
|
Peptide Fragments | 13 | 2024 | 5097 | 0.690 |
Why?
|
Disease Management | 3 | 2024 | 2459 | 0.690 |
Why?
|
Takotsubo Cardiomyopathy | 1 | 2021 | 125 | 0.690 |
Why?
|
Tricuspid Valve Insufficiency | 1 | 2023 | 349 | 0.670 |
Why?
|
Atherosclerosis | 15 | 2024 | 3445 | 0.670 |
Why?
|
Adrenal Gland Neoplasms | 2 | 2021 | 740 | 0.660 |
Why?
|
Appetite Regulation | 1 | 2019 | 88 | 0.650 |
Why?
|
Risk Factors | 73 | 2024 | 72290 | 0.640 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 2 | 2023 | 236 | 0.640 |
Why?
|
Female | 169 | 2024 | 380194 | 0.630 |
Why?
|
Diabetes Mellitus | 8 | 2022 | 5751 | 0.630 |
Why?
|
Myocardial Ischemia | 11 | 2016 | 2148 | 0.630 |
Why?
|
Sodium Channel Blockers | 3 | 2015 | 176 | 0.620 |
Why?
|
Registries | 19 | 2017 | 8089 | 0.620 |
Why?
|
Thrombosis | 9 | 2021 | 2968 | 0.610 |
Why?
|
Albuminuria | 3 | 2022 | 682 | 0.610 |
Why?
|
Renal Insufficiency | 4 | 2020 | 804 | 0.610 |
Why?
|
Peripheral Arterial Disease | 10 | 2021 | 1188 | 0.590 |
Why?
|
Overweight | 6 | 2023 | 2371 | 0.580 |
Why?
|
Kidney | 6 | 2024 | 7186 | 0.570 |
Why?
|
Benzhydryl Compounds | 8 | 2024 | 845 | 0.570 |
Why?
|
Hypoglycemia | 5 | 2018 | 861 | 0.570 |
Why?
|
Enzyme Inhibitors | 14 | 2014 | 3798 | 0.560 |
Why?
|
Critical Pathways | 3 | 2019 | 476 | 0.550 |
Why?
|
Triage | 2 | 2020 | 976 | 0.550 |
Why?
|
Metformin | 2 | 2020 | 835 | 0.540 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2021 | 3255 | 0.520 |
Why?
|
Glycopeptides | 2 | 2015 | 224 | 0.510 |
Why?
|
Fibrinolytic Agents | 8 | 2020 | 2158 | 0.510 |
Why?
|
Outpatients | 2 | 2020 | 1486 | 0.500 |
Why?
|
Troponin I | 5 | 2021 | 619 | 0.490 |
Why?
|
Medical Informatics | 1 | 2021 | 745 | 0.490 |
Why?
|
Atrial Fibrillation | 6 | 2023 | 5034 | 0.480 |
Why?
|
Body Temperature Regulation | 1 | 2015 | 252 | 0.480 |
Why?
|
Cardiovascular Agents | 8 | 2021 | 850 | 0.480 |
Why?
|
Coronary Disease | 6 | 2018 | 6077 | 0.470 |
Why?
|
Diabetes Complications | 2 | 2020 | 1359 | 0.470 |
Why?
|
Treatment Outcome | 63 | 2022 | 63114 | 0.470 |
Why?
|
Hypoxia-Ischemia, Brain | 4 | 2022 | 333 | 0.460 |
Why?
|
Enoxaparin | 3 | 2007 | 377 | 0.460 |
Why?
|
Kidney Diseases | 3 | 2019 | 2149 | 0.460 |
Why?
|
Emergency Service, Hospital | 8 | 2023 | 7659 | 0.460 |
Why?
|
Fumarates | 2 | 2013 | 132 | 0.460 |
Why?
|
Blood Pressure | 6 | 2023 | 8554 | 0.450 |
Why?
|
Myocardial Revascularization | 7 | 2016 | 841 | 0.440 |
Why?
|
Critical Care | 4 | 2015 | 2647 | 0.440 |
Why?
|
Tropanes | 3 | 2021 | 51 | 0.430 |
Why?
|
Myocardial Reperfusion | 1 | 2014 | 351 | 0.420 |
Why?
|
Clinical Protocols | 3 | 2015 | 1462 | 0.420 |
Why?
|
Valine | 2 | 2013 | 413 | 0.420 |
Why?
|
Program Development | 1 | 2019 | 1316 | 0.420 |
Why?
|
Coronary Circulation | 5 | 2014 | 1572 | 0.420 |
Why?
|
Lipid Metabolism | 1 | 2020 | 1889 | 0.410 |
Why?
|
Stroke | 24 | 2021 | 9981 | 0.410 |
Why?
|
Obesity | 7 | 2024 | 12745 | 0.400 |
Why?
|
Muscarinic Antagonists | 3 | 2021 | 137 | 0.400 |
Why?
|
Shock, Cardiogenic | 6 | 2021 | 688 | 0.400 |
Why?
|
Ventricular Dysfunction, Left | 6 | 2023 | 2073 | 0.390 |
Why?
|
Life Support Systems | 1 | 2010 | 11 | 0.390 |
Why?
|
Amides | 2 | 2013 | 459 | 0.390 |
Why?
|
Time Factors | 34 | 2021 | 40075 | 0.390 |
Why?
|
Renin-Angiotensin System | 2 | 2013 | 759 | 0.380 |
Why?
|
Resuscitation | 1 | 2015 | 658 | 0.380 |
Why?
|
Stroke Volume | 11 | 2023 | 5007 | 0.380 |
Why?
|
Arthroplasty, Replacement, Knee | 2 | 2021 | 1458 | 0.380 |
Why?
|
Spironolactone | 1 | 2014 | 382 | 0.380 |
Why?
|
Kaplan-Meier Estimate | 22 | 2019 | 6538 | 0.380 |
Why?
|
Angioplasty, Balloon, Coronary | 11 | 2012 | 1873 | 0.370 |
Why?
|
Prognosis | 33 | 2024 | 29063 | 0.370 |
Why?
|
Protein Precursors | 3 | 2014 | 1154 | 0.360 |
Why?
|
Electroencephalography | 7 | 2022 | 6150 | 0.350 |
Why?
|
Bradycardia | 1 | 2011 | 307 | 0.340 |
Why?
|
Electrocardiography, Ambulatory | 5 | 2013 | 585 | 0.330 |
Why?
|
Tetrazoles | 2 | 2013 | 835 | 0.320 |
Why?
|
Cause of Death | 8 | 2021 | 3584 | 0.320 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 3 | 2021 | 1518 | 0.320 |
Why?
|
Aldosterone | 1 | 2013 | 877 | 0.310 |
Why?
|
Pyrrolidines | 2 | 2007 | 342 | 0.310 |
Why?
|
Hospital Mortality | 9 | 2016 | 5317 | 0.310 |
Why?
|
Proportional Hazards Models | 19 | 2021 | 12354 | 0.300 |
Why?
|
Hyperglycemia | 3 | 2015 | 1373 | 0.300 |
Why?
|
Hemorrhage | 15 | 2020 | 3461 | 0.290 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 1 | 2010 | 451 | 0.290 |
Why?
|
Diabetic Nephropathies | 5 | 2018 | 984 | 0.290 |
Why?
|
Placebos | 5 | 2019 | 1676 | 0.280 |
Why?
|
Death | 5 | 2020 | 678 | 0.280 |
Why?
|
Incidence | 22 | 2023 | 20947 | 0.280 |
Why?
|
Acute Disease | 10 | 2019 | 7149 | 0.280 |
Why?
|
Incretins | 2 | 2018 | 88 | 0.270 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 4 | 2021 | 3047 | 0.270 |
Why?
|
Ventricular Function, Left | 3 | 2019 | 3670 | 0.270 |
Why?
|
Ambulatory Care | 2 | 2019 | 2708 | 0.270 |
Why?
|
Telemedicine | 3 | 2020 | 2872 | 0.270 |
Why?
|
Creatine Kinase | 2 | 2004 | 694 | 0.260 |
Why?
|
Follow-Up Studies | 27 | 2019 | 39050 | 0.260 |
Why?
|
Cardiac Output, Low | 1 | 2006 | 195 | 0.260 |
Why?
|
Coronary Artery Bypass | 8 | 2016 | 2289 | 0.260 |
Why?
|
Recurrence | 13 | 2016 | 8340 | 0.260 |
Why?
|
Survival Rate | 15 | 2016 | 12788 | 0.250 |
Why?
|
Anti-Obesity Agents | 2 | 2018 | 217 | 0.250 |
Why?
|
Fatal Outcome | 3 | 2021 | 1850 | 0.250 |
Why?
|
Delivery of Health Care | 2 | 2023 | 5319 | 0.250 |
Why?
|
Cholesterol, LDL | 3 | 2023 | 2356 | 0.250 |
Why?
|
Coronary Angiography | 11 | 2016 | 4577 | 0.250 |
Why?
|
Creatine Kinase, MB Form | 4 | 2014 | 214 | 0.250 |
Why?
|
Antithrombins | 1 | 2007 | 304 | 0.240 |
Why?
|
Growth Differentiation Factor 15 | 2 | 2019 | 176 | 0.240 |
Why?
|
Glucose | 1 | 2016 | 4397 | 0.230 |
Why?
|
Tachycardia | 2 | 2021 | 619 | 0.230 |
Why?
|
Recovery of Function | 6 | 2021 | 2925 | 0.230 |
Why?
|
Predictive Value of Tests | 14 | 2019 | 15076 | 0.220 |
Why?
|
Monitoring, Physiologic | 1 | 2010 | 1738 | 0.220 |
Why?
|
Survival Analysis | 9 | 2019 | 10252 | 0.220 |
Why?
|
Isoenzymes | 2 | 2004 | 1726 | 0.220 |
Why?
|
Ketosis | 1 | 2022 | 49 | 0.210 |
Why?
|
Dipeptidyl Peptidase 4 | 1 | 2022 | 91 | 0.210 |
Why?
|
Anticoagulants | 6 | 2023 | 4599 | 0.210 |
Why?
|
Thiophenes | 3 | 2015 | 588 | 0.210 |
Why?
|
Purinergic P2Y Receptor Antagonists | 3 | 2016 | 361 | 0.210 |
Why?
|
Quality Improvement | 2 | 2016 | 3749 | 0.210 |
Why?
|
Thrombocytopenia | 2 | 2007 | 1179 | 0.200 |
Why?
|
Pharmacists | 1 | 2024 | 248 | 0.200 |
Why?
|
Pregnancy Complications, Cardiovascular | 1 | 2006 | 500 | 0.200 |
Why?
|
Emergency Medical Services | 1 | 2013 | 1917 | 0.190 |
Why?
|
Early Termination of Clinical Trials | 1 | 2021 | 68 | 0.190 |
Why?
|
Coronary Thrombosis | 2 | 2014 | 495 | 0.190 |
Why?
|
Inpatients | 1 | 2012 | 2518 | 0.190 |
Why?
|
Prospective Studies | 20 | 2022 | 53288 | 0.190 |
Why?
|
Adrenergic beta-2 Receptor Agonists | 1 | 2021 | 104 | 0.190 |
Why?
|
Thrombin | 3 | 2021 | 598 | 0.190 |
Why?
|
Aged, 80 and over | 20 | 2020 | 57776 | 0.190 |
Why?
|
Adrenergic beta-Antagonists | 3 | 2021 | 1240 | 0.180 |
Why?
|
Weight Loss | 4 | 2019 | 2622 | 0.180 |
Why?
|
Glycosides | 1 | 2020 | 107 | 0.180 |
Why?
|
Myoclonus | 1 | 2020 | 104 | 0.180 |
Why?
|
Inflammation | 2 | 2019 | 10638 | 0.180 |
Why?
|
Randomized Controlled Trials as Topic | 12 | 2019 | 9959 | 0.170 |
Why?
|
Coma | 2 | 2015 | 475 | 0.170 |
Why?
|
Cohort Studies | 12 | 2024 | 40561 | 0.170 |
Why?
|
Multivariate Analysis | 10 | 2017 | 12245 | 0.170 |
Why?
|
Automation | 1 | 2021 | 584 | 0.170 |
Why?
|
Patient Discharge | 6 | 2019 | 3313 | 0.170 |
Why?
|
Blood Glucose | 6 | 2021 | 6256 | 0.160 |
Why?
|
Disease Progression | 9 | 2023 | 13284 | 0.160 |
Why?
|
Echocardiography | 3 | 2021 | 5102 | 0.160 |
Why?
|
United States Food and Drug Administration | 4 | 2020 | 1584 | 0.160 |
Why?
|
Algorithms | 8 | 2020 | 13881 | 0.160 |
Why?
|
Purinergic P2 Receptor Antagonists | 2 | 2009 | 71 | 0.160 |
Why?
|
Lung Neoplasms | 1 | 2023 | 13102 | 0.160 |
Why?
|
Pulmonary Edema | 1 | 2021 | 414 | 0.160 |
Why?
|
Ischemia | 3 | 2021 | 1907 | 0.160 |
Why?
|
Sex Factors | 8 | 2021 | 10397 | 0.160 |
Why?
|
Heart Valve Diseases | 1 | 2006 | 1073 | 0.160 |
Why?
|
Neurologic Examination | 2 | 2018 | 930 | 0.150 |
Why?
|
Radiography, Thoracic | 2 | 2021 | 1265 | 0.150 |
Why?
|
Drug Therapy | 1 | 2021 | 497 | 0.150 |
Why?
|
Anticholesteremic Agents | 1 | 2005 | 979 | 0.150 |
Why?
|
Syndrome | 5 | 2007 | 3251 | 0.150 |
Why?
|
Decision Support Techniques | 3 | 2019 | 1956 | 0.150 |
Why?
|
Dyspnea | 3 | 2023 | 1303 | 0.150 |
Why?
|
United States | 23 | 2023 | 69872 | 0.150 |
Why?
|
Signal Processing, Computer-Assisted | 2 | 2016 | 1534 | 0.150 |
Why?
|
Aspirin | 5 | 2014 | 3282 | 0.150 |
Why?
|
Information Storage and Retrieval | 1 | 2022 | 824 | 0.140 |
Why?
|
Workflow | 1 | 2021 | 847 | 0.140 |
Why?
|
Pancreatitis | 2 | 2014 | 1092 | 0.140 |
Why?
|
Quality of Life | 7 | 2023 | 12804 | 0.140 |
Why?
|
Myocardium | 3 | 2021 | 4776 | 0.140 |
Why?
|
Neopterin | 2 | 2011 | 56 | 0.140 |
Why?
|
Drug Labeling | 1 | 2018 | 233 | 0.140 |
Why?
|
Electronic Health Records | 3 | 2022 | 4468 | 0.140 |
Why?
|
Electric Countershock | 1 | 2019 | 534 | 0.140 |
Why?
|
Drug Administration Schedule | 3 | 2015 | 4933 | 0.140 |
Why?
|
Collagen Type I | 1 | 2019 | 592 | 0.140 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 3 | 2010 | 641 | 0.140 |
Why?
|
Cardiopulmonary Resuscitation | 3 | 2015 | 980 | 0.130 |
Why?
|
Risk | 7 | 2019 | 9687 | 0.130 |
Why?
|
Retrospective Studies | 17 | 2023 | 77449 | 0.130 |
Why?
|
Infarction | 1 | 2017 | 244 | 0.130 |
Why?
|
Diet, Reducing | 1 | 2019 | 462 | 0.130 |
Why?
|
Peripheral Vascular Diseases | 1 | 2018 | 550 | 0.130 |
Why?
|
Calibration | 1 | 2017 | 816 | 0.130 |
Why?
|
Anti-Arrhythmia Agents | 1 | 2019 | 789 | 0.130 |
Why?
|
Physical Stimulation | 1 | 2016 | 525 | 0.130 |
Why?
|
Alanine | 2 | 2007 | 572 | 0.120 |
Why?
|
Endpoint Determination | 1 | 2017 | 601 | 0.120 |
Why?
|
Electrodiagnosis | 1 | 2015 | 151 | 0.120 |
Why?
|
Drug Therapy, Combination | 7 | 2021 | 6489 | 0.120 |
Why?
|
Lung | 3 | 2021 | 9856 | 0.120 |
Why?
|
Body Mass Index | 7 | 2024 | 12720 | 0.120 |
Why?
|
Dose-Response Relationship, Drug | 7 | 2021 | 10943 | 0.120 |
Why?
|
Exercise Test | 3 | 2016 | 2074 | 0.110 |
Why?
|
Galvanic Skin Response | 1 | 2015 | 349 | 0.110 |
Why?
|
Military Personnel | 1 | 2022 | 1133 | 0.110 |
Why?
|
Pravastatin | 3 | 2016 | 395 | 0.110 |
Why?
|
Coronary Occlusion | 1 | 2016 | 304 | 0.110 |
Why?
|
Brain Waves | 1 | 2017 | 401 | 0.110 |
Why?
|
Ischemic Attack, Transient | 2 | 2015 | 935 | 0.110 |
Why?
|
Practice Guidelines as Topic | 6 | 2020 | 7279 | 0.110 |
Why?
|
Autonomic Nervous System Diseases | 1 | 2015 | 257 | 0.110 |
Why?
|
Confidence Intervals | 4 | 2014 | 2971 | 0.110 |
Why?
|
Cholesterol | 1 | 2021 | 2917 | 0.110 |
Why?
|
Pregnancy-Associated Plasma Protein-A | 1 | 2012 | 55 | 0.100 |
Why?
|
Thiazolidinediones | 1 | 2015 | 476 | 0.100 |
Why?
|
Forced Expiratory Volume | 3 | 2021 | 1743 | 0.100 |
Why?
|
Acoustic Stimulation | 1 | 2016 | 1216 | 0.100 |
Why?
|
Patient Admission | 2 | 2019 | 1380 | 0.100 |
Why?
|
Prescriptions | 1 | 2015 | 387 | 0.100 |
Why?
|
Coronary Care Units | 1 | 2013 | 214 | 0.100 |
Why?
|
Risk Reduction Behavior | 1 | 2019 | 1125 | 0.100 |
Why?
|
Vascular Patency | 2 | 2016 | 886 | 0.100 |
Why?
|
Mortality | 2 | 2021 | 2864 | 0.100 |
Why?
|
Prevalence | 6 | 2018 | 15226 | 0.100 |
Why?
|
Logistic Models | 7 | 2017 | 13408 | 0.100 |
Why?
|
Fatty Acids, Omega-3 | 1 | 2021 | 1344 | 0.100 |
Why?
|
Vascular Surgical Procedures | 2 | 2020 | 1475 | 0.100 |
Why?
|
Aortic Valve Stenosis | 1 | 2024 | 1965 | 0.100 |
Why?
|
Cerebrovascular Disorders | 1 | 2018 | 1504 | 0.100 |
Why?
|
Osteoprotegerin | 1 | 2012 | 176 | 0.100 |
Why?
|
Odds Ratio | 6 | 2016 | 9849 | 0.100 |
Why?
|
Thoracic Surgical Procedures | 1 | 2015 | 342 | 0.100 |
Why?
|
Sodium-Glucose Transporter 2 | 2 | 2023 | 85 | 0.090 |
Why?
|
Advisory Committees | 1 | 2015 | 775 | 0.090 |
Why?
|
Platelet Activation | 2 | 2011 | 673 | 0.090 |
Why?
|
Diabetic Angiopathies | 3 | 2015 | 818 | 0.090 |
Why?
|
Placebo Effect | 1 | 2014 | 502 | 0.090 |
Why?
|
Osteoporotic Fractures | 1 | 2015 | 401 | 0.090 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2011 | 257 | 0.090 |
Why?
|
Thromboembolism | 1 | 2017 | 986 | 0.090 |
Why?
|
France | 1 | 2011 | 517 | 0.090 |
Why?
|
Cardiomyopathies | 1 | 2022 | 1912 | 0.090 |
Why?
|
Intracranial Hemorrhages | 2 | 2013 | 855 | 0.090 |
Why?
|
Comorbidity | 6 | 2015 | 10388 | 0.090 |
Why?
|
Omeprazole | 1 | 2010 | 112 | 0.090 |
Why?
|
Temperature | 1 | 2016 | 2206 | 0.090 |
Why?
|
Brain Injuries | 1 | 2022 | 2025 | 0.090 |
Why?
|
Reproducibility of Results | 4 | 2021 | 19905 | 0.090 |
Why?
|
Ventricular Premature Complexes | 1 | 2010 | 111 | 0.090 |
Why?
|
Brain Diseases | 1 | 2018 | 1563 | 0.090 |
Why?
|
Drug Prescriptions | 1 | 2018 | 1637 | 0.080 |
Why?
|
Severity of Illness Index | 6 | 2021 | 15540 | 0.080 |
Why?
|
Age Factors | 6 | 2019 | 18370 | 0.080 |
Why?
|
Israel | 1 | 2011 | 796 | 0.080 |
Why?
|
Conscious Sedation | 1 | 2013 | 528 | 0.080 |
Why?
|
Defibrillators, Implantable | 2 | 2016 | 1440 | 0.080 |
Why?
|
Analgesia | 1 | 2013 | 461 | 0.080 |
Why?
|
Fibrinolysis | 1 | 2010 | 322 | 0.080 |
Why?
|
Antihypertensive Agents | 1 | 2018 | 2046 | 0.080 |
Why?
|
Heptanoic Acids | 2 | 2011 | 343 | 0.080 |
Why?
|
Drug Approval | 1 | 2015 | 742 | 0.080 |
Why?
|
Age Distribution | 1 | 2014 | 2902 | 0.080 |
Why?
|
Heart Conduction System | 1 | 2014 | 1047 | 0.080 |
Why?
|
Venous Thromboembolism | 1 | 2021 | 1671 | 0.080 |
Why?
|
Obesity, Abdominal | 1 | 2011 | 361 | 0.080 |
Why?
|
Length of Stay | 2 | 2019 | 6309 | 0.080 |
Why?
|
Pilot Projects | 2 | 2019 | 8324 | 0.080 |
Why?
|
Renin | 1 | 2010 | 642 | 0.080 |
Why?
|
Patient Care Team | 1 | 2019 | 2531 | 0.080 |
Why?
|
Independent Living | 1 | 2012 | 568 | 0.080 |
Why?
|
Health Status Disparities | 1 | 2020 | 1797 | 0.080 |
Why?
|
Drug-Eluting Stents | 1 | 2014 | 753 | 0.080 |
Why?
|
Cardiology | 2 | 2019 | 1668 | 0.080 |
Why?
|
Bronchodilator Agents | 2 | 2021 | 502 | 0.080 |
Why?
|
Adult | 19 | 2023 | 214055 | 0.080 |
Why?
|
Peroxidase | 1 | 2010 | 611 | 0.080 |
Why?
|
Administration, Inhalation | 2 | 2021 | 1105 | 0.070 |
Why?
|
Insulin-Secreting Cells | 1 | 2015 | 891 | 0.070 |
Why?
|
Family Characteristics | 1 | 2012 | 1000 | 0.070 |
Why?
|
Warfarin | 3 | 2023 | 1496 | 0.070 |
Why?
|
Longitudinal Studies | 3 | 2024 | 13989 | 0.070 |
Why?
|
Postoperative Hemorrhage | 1 | 2010 | 413 | 0.070 |
Why?
|
Data Mining | 1 | 2012 | 537 | 0.070 |
Why?
|
Chi-Square Distribution | 4 | 2016 | 3508 | 0.070 |
Why?
|
Endovascular Procedures | 2 | 2020 | 1979 | 0.070 |
Why?
|
Peptides | 1 | 2019 | 4409 | 0.070 |
Why?
|
Evidence-Based Practice | 1 | 2010 | 500 | 0.070 |
Why?
|
Insulin | 3 | 2016 | 6580 | 0.070 |
Why?
|
Evidence-Based Medicine | 4 | 2014 | 3610 | 0.070 |
Why?
|
Life Style | 1 | 2017 | 3835 | 0.070 |
Why?
|
Research Design | 4 | 2019 | 5987 | 0.070 |
Why?
|
Proton Pump Inhibitors | 1 | 2010 | 526 | 0.070 |
Why?
|
Down-Regulation | 1 | 2013 | 3002 | 0.070 |
Why?
|
Diagnostic Techniques, Cardiovascular | 1 | 2006 | 153 | 0.070 |
Why?
|
Heart-Assist Devices | 1 | 2015 | 1194 | 0.060 |
Why?
|
Ventricular Function | 1 | 2006 | 416 | 0.060 |
Why?
|
Interdisciplinary Communication | 1 | 2010 | 950 | 0.060 |
Why?
|
Iron | 1 | 2013 | 1774 | 0.060 |
Why?
|
Electrophysiology | 1 | 2007 | 1308 | 0.060 |
Why?
|
Magnetic Resonance Imaging | 3 | 2022 | 35421 | 0.060 |
Why?
|
Probability | 1 | 2010 | 2505 | 0.060 |
Why?
|
Diagnosis, Differential | 2 | 2019 | 12959 | 0.060 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2015 | 1354 | 0.060 |
Why?
|
Patient Selection | 2 | 2019 | 4215 | 0.060 |
Why?
|
Pyrroles | 2 | 2011 | 1146 | 0.060 |
Why?
|
Physicians | 1 | 2022 | 4567 | 0.060 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2009 | 719 | 0.060 |
Why?
|
Heart Diseases | 1 | 2016 | 2788 | 0.060 |
Why?
|
Chronic Disease | 4 | 2016 | 9146 | 0.060 |
Why?
|
Medication Adherence | 1 | 2015 | 2063 | 0.060 |
Why?
|
Brain Ischemia | 2 | 2014 | 3265 | 0.060 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2010 | 1130 | 0.060 |
Why?
|
Referral and Consultation | 1 | 2016 | 3528 | 0.050 |
Why?
|
Sensitivity and Specificity | 4 | 2018 | 14722 | 0.050 |
Why?
|
Decision Making | 1 | 2016 | 3887 | 0.050 |
Why?
|
Regression Analysis | 1 | 2012 | 6459 | 0.050 |
Why?
|
Informatics | 1 | 2022 | 72 | 0.050 |
Why?
|
Retreatment | 2 | 2015 | 610 | 0.050 |
Why?
|
Respiration, Artificial | 1 | 2013 | 2569 | 0.050 |
Why?
|
Receptors, Cell Surface | 1 | 2011 | 2866 | 0.050 |
Why?
|
Gastric Inhibitory Polypeptide | 1 | 2022 | 59 | 0.050 |
Why?
|
Patient Readmission | 1 | 2016 | 3114 | 0.050 |
Why?
|
Lipoproteins, LDL | 1 | 2005 | 640 | 0.050 |
Why?
|
Genome-Wide Association Study | 1 | 2020 | 12261 | 0.050 |
Why?
|
Massachusetts | 1 | 2014 | 8663 | 0.050 |
Why?
|
Analysis of Variance | 1 | 2010 | 6365 | 0.050 |
Why?
|
Ketones | 1 | 2022 | 188 | 0.050 |
Why?
|
Receptors, Angiotensin | 1 | 2021 | 142 | 0.050 |
Why?
|
Sodium-Glucose Transporter 1 | 1 | 2020 | 112 | 0.050 |
Why?
|
Bilirubin | 1 | 2022 | 425 | 0.050 |
Why?
|
Apolipoproteins E | 1 | 2006 | 1438 | 0.050 |
Why?
|
Biology | 1 | 2022 | 294 | 0.050 |
Why?
|
Choline | 1 | 2022 | 493 | 0.050 |
Why?
|
Lipoprotein(a) | 1 | 2024 | 435 | 0.040 |
Why?
|
Creatine | 1 | 2022 | 421 | 0.040 |
Why?
|
Creatinine | 2 | 2016 | 1919 | 0.040 |
Why?
|
Hirudins | 2 | 2010 | 183 | 0.040 |
Why?
|
Aspartic Acid | 1 | 2022 | 576 | 0.040 |
Why?
|
Diet | 1 | 2017 | 7939 | 0.040 |
Why?
|
Models, Cardiovascular | 2 | 2017 | 996 | 0.040 |
Why?
|
Models, Animal | 1 | 2006 | 2171 | 0.040 |
Why?
|
Product Labeling | 1 | 2020 | 79 | 0.040 |
Why?
|
Computational Biology | 1 | 2011 | 3521 | 0.040 |
Why?
|
Drug Utilization | 2 | 2019 | 1183 | 0.040 |
Why?
|
Extremities | 2 | 2016 | 865 | 0.040 |
Why?
|
Vital Capacity | 1 | 2021 | 925 | 0.040 |
Why?
|
Stents | 2 | 2008 | 3280 | 0.040 |
Why?
|
Medical History Taking | 1 | 2022 | 783 | 0.040 |
Why?
|
Neprilysin | 1 | 2021 | 439 | 0.040 |
Why?
|
Internationality | 2 | 2015 | 1003 | 0.040 |
Why?
|
Heparin | 3 | 2010 | 1637 | 0.040 |
Why?
|
Medicare | 1 | 2016 | 6566 | 0.040 |
Why?
|
Mycoses | 1 | 2020 | 376 | 0.040 |
Why?
|
Diabetic Ketoacidosis | 1 | 2020 | 245 | 0.040 |
Why?
|
Models, Statistical | 1 | 2012 | 5102 | 0.040 |
Why?
|
Evaluation Studies as Topic | 1 | 2019 | 1681 | 0.040 |
Why?
|
Renal Dialysis | 1 | 2006 | 1786 | 0.040 |
Why?
|
Databases, Factual | 2 | 2022 | 7729 | 0.040 |
Why?
|
Pancreatic Neoplasms | 1 | 2014 | 5256 | 0.040 |
Why?
|
Consciousness | 1 | 2022 | 572 | 0.030 |
Why?
|
Canada | 1 | 2021 | 2065 | 0.030 |
Why?
|
Systole | 1 | 2018 | 958 | 0.030 |
Why?
|
Diastole | 1 | 2018 | 791 | 0.030 |
Why?
|
Glyburide | 1 | 2016 | 113 | 0.030 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2021 | 924 | 0.030 |
Why?
|
Sulfonylurea Compounds | 1 | 2016 | 204 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2021 | 2715 | 0.030 |
Why?
|
Insulin Resistance | 2 | 2021 | 3864 | 0.030 |
Why?
|
Fatty Acids | 1 | 2022 | 1809 | 0.030 |
Why?
|
Limb Salvage | 1 | 2016 | 433 | 0.030 |
Why?
|
Aortic Valve Insufficiency | 1 | 2018 | 579 | 0.030 |
Why?
|
Kidney Failure, Chronic | 1 | 2006 | 2538 | 0.030 |
Why?
|
International Agencies | 1 | 2014 | 240 | 0.030 |
Why?
|
Diarrhea | 1 | 2020 | 1348 | 0.030 |
Why?
|
Serum Albumin | 1 | 2016 | 676 | 0.030 |
Why?
|
Recombinant Proteins | 3 | 2010 | 6622 | 0.030 |
Why?
|
Patient-Centered Care | 1 | 2023 | 1439 | 0.030 |
Why?
|
Endothelial Cells | 1 | 2006 | 3479 | 0.030 |
Why?
|
Hemodynamics | 2 | 2015 | 4199 | 0.030 |
Why?
|
Prediabetic State | 1 | 2018 | 499 | 0.030 |
Why?
|
Brugada Syndrome | 1 | 2014 | 97 | 0.030 |
Why?
|
Remission Induction | 1 | 2018 | 2386 | 0.030 |
Why?
|
Atrial Natriuretic Factor | 1 | 2014 | 393 | 0.030 |
Why?
|
Patient Care Planning | 1 | 2018 | 921 | 0.030 |
Why?
|
Ankle Brachial Index | 1 | 2013 | 154 | 0.030 |
Why?
|
Discriminant Analysis | 1 | 2012 | 235 | 0.030 |
Why?
|
Sodium | 1 | 2017 | 1623 | 0.030 |
Why?
|
Heart Rate | 2 | 2014 | 4091 | 0.030 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2022 | 3760 | 0.020 |
Why?
|
Catalysis | 1 | 2013 | 761 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2020 | 21746 | 0.020 |
Why?
|
Norway | 1 | 2012 | 448 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2014 | 20129 | 0.020 |
Why?
|
Loneliness | 1 | 2012 | 185 | 0.020 |
Why?
|
Platelet Function Tests | 1 | 2011 | 270 | 0.020 |
Why?
|
Calcium Channel Blockers | 1 | 2013 | 690 | 0.020 |
Why?
|
Clinical Trials as Topic | 2 | 2011 | 7913 | 0.020 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2022 | 2737 | 0.020 |
Why?
|
Emergency Medicine | 1 | 2019 | 1207 | 0.020 |
Why?
|
Administration, Oral | 2 | 2008 | 3913 | 0.020 |
Why?
|
Heart | 1 | 2023 | 4467 | 0.020 |
Why?
|
Thiazoles | 1 | 2017 | 1483 | 0.020 |
Why?
|
Pregnancy | 2 | 2012 | 29144 | 0.020 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2010 | 339 | 0.020 |
Why?
|
Fasting | 1 | 2015 | 1593 | 0.020 |
Why?
|
Dyslipidemias | 1 | 2015 | 849 | 0.020 |
Why?
|
Hypertension, Pulmonary | 1 | 2018 | 1537 | 0.020 |
Why?
|
Body Weight | 1 | 2018 | 4669 | 0.020 |
Why?
|
Waist Circumference | 1 | 2011 | 917 | 0.020 |
Why?
|
Pharmacogenetics | 1 | 2011 | 675 | 0.020 |
Why?
|
Cardiac Surgical Procedures | 2 | 2014 | 3537 | 0.020 |
Why?
|
Oxidation-Reduction | 1 | 2013 | 2187 | 0.020 |
Why?
|
Receptors, Purinergic P2Y12 | 1 | 2007 | 132 | 0.020 |
Why?
|
Homozygote | 1 | 2011 | 1785 | 0.020 |
Why?
|
Neoplasms | 1 | 2015 | 21683 | 0.020 |
Why?
|
Anthropometry | 1 | 2011 | 1350 | 0.020 |
Why?
|
Immunoassay | 1 | 2010 | 752 | 0.020 |
Why?
|
India | 1 | 2013 | 2197 | 0.020 |
Why?
|
International Cooperation | 1 | 2013 | 1420 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2019 | 3679 | 0.020 |
Why?
|
Health Status | 1 | 2019 | 4034 | 0.020 |
Why?
|
Glucose Tolerance Test | 1 | 2009 | 1150 | 0.020 |
Why?
|
Drug Interactions | 1 | 2010 | 1460 | 0.020 |
Why?
|
Europe | 1 | 2012 | 3339 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2016 | 2759 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2013 | 2077 | 0.020 |
Why?
|
Postoperative Complications | 2 | 2021 | 15295 | 0.020 |
Why?
|
Truth Disclosure | 1 | 2009 | 436 | 0.020 |
Why?
|
Brain | 2 | 2022 | 26385 | 0.020 |
Why?
|
Heterozygote | 1 | 2011 | 2804 | 0.020 |
Why?
|
Sex Distribution | 1 | 2010 | 2297 | 0.020 |
Why?
|
Goals | 1 | 2010 | 706 | 0.020 |
Why?
|
Young Adult | 2 | 2023 | 56430 | 0.020 |
Why?
|
Exercise Tolerance | 1 | 2009 | 770 | 0.010 |
Why?
|
Drug Resistance | 1 | 2010 | 1609 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 3870 | 0.010 |
Why?
|
Boston | 1 | 2016 | 9313 | 0.010 |
Why?
|
Societies, Medical | 1 | 2015 | 3743 | 0.010 |
Why?
|
Terminology as Topic | 1 | 2010 | 1547 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8388 | 0.010 |
Why?
|
Education, Medical, Graduate | 1 | 2015 | 2291 | 0.010 |
Why?
|
Linear Models | 1 | 2013 | 5952 | 0.010 |
Why?
|
Long-Term Care | 1 | 2006 | 607 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2024 | 17446 | 0.010 |
Why?
|
Microcirculation | 1 | 2006 | 1286 | 0.010 |
Why?
|
Quality Indicators, Health Care | 1 | 2012 | 1831 | 0.010 |
Why?
|
Multicenter Studies as Topic | 1 | 2006 | 1677 | 0.010 |
Why?
|
Surgical Procedures, Operative | 1 | 2012 | 1876 | 0.010 |
Why?
|
Guideline Adherence | 1 | 2010 | 2266 | 0.010 |
Why?
|
Child, Preschool | 1 | 2022 | 41006 | 0.010 |
Why?
|
Sex Characteristics | 1 | 2010 | 2585 | 0.010 |
Why?
|
Clinical Competence | 1 | 2015 | 4687 | 0.010 |
Why?
|
Artificial Intelligence | 1 | 2012 | 2214 | 0.010 |
Why?
|
Smoking | 1 | 2015 | 8987 | 0.010 |
Why?
|
Streptokinase | 1 | 1998 | 188 | 0.010 |
Why?
|
Ultrasonography | 1 | 2011 | 5985 | 0.010 |
Why?
|
Vascular Diseases | 1 | 2006 | 1161 | 0.010 |
Why?
|
Genotype | 1 | 2011 | 12951 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2009 | 8642 | 0.010 |
Why?
|
Adolescent | 2 | 2017 | 85781 | 0.010 |
Why?
|
Child | 1 | 2022 | 77709 | 0.010 |
Why?
|
Animals | 1 | 2006 | 168757 | 0.010 |
Why?
|
Tissue Plasminogen Activator | 1 | 1998 | 1261 | 0.010 |
Why?
|
Emergencies | 1 | 1998 | 1170 | 0.010 |
Why?
|
Hospitals | 1 | 2005 | 3952 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 2005 | 3843 | 0.010 |
Why?
|